Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bio-Rad Laboratories, a global manufacturer and distributor of life science research and clinical diagnostic products, has acquired GnuBIO, a US-based privately-held life sciences firm that has developed a droplet-based DNA sequencing technology.
Subscribe to our email newsletter
With the acquisition, Bio-Rad will expand its Digital Biology Center as well as establish a research and development site in Cambridge, Massachusetts.
GnuBIO has developed a DNA sequencing solution that integrates the complete sample preparation workflow on a chip, from sample capture, PCR, and sequencing, to informatics.
The company said that this capability provides a ‘Sample In, Answer Out’ DNA sequencing solution whereby a technician or researcher simply loads genomic DNA into the cartridge and presses a button to start the run with results delivered within hours, versus days.
GnuBIO president, founder and CEO John Boyce said Bio-Rad’s leading positions in the clinical IVD market as well as the Droplet Digital PCR space make Bio-Rad the ideal acquisition partner for the company.
"Bio-Rad’s reputation as well as its presence in both the clinical and research markets will be essential elements to the success of the GnuBIO platform," Boyce said.
Bio-Rad designs, manufactures, and distributes a broad range of new products and solutions for the life science research and clinical diagnostic markets.